Study Title
A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients with CAIX-positive Cancer
Study Details
Description:
Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.
Sponsor:
Philogen S.p.A.
Contacts:
Jacqueline Mock, PhDregulatory@philogen.com
+41 43 544 88 02
Federica Bastioli (Pharmaceutical Chemist)regulatory@philogen.com
+39 057717816
Government Study Link:
NCT06840548 - Click here to see study onClinicalTrials.gov
Drug Details
68Ga-OncoCAIX
Isotope(s):
- GALLIUM-68
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- CAIX
